Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Drug companies are sprinting ahead in a race against the clock to deliver millions of doses of vaccine for the H1N1 influenza virus before cooler weather ushers in the 2009-2010 flu season. A two-part cover story in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine, focuses on that topic and efforts to develop antiviral drugs for flu infections.
WellCare Health Plans, Inc. (NYSE: WCG) announced it will cover the full cost of administration of the H1N1 vaccine as a preventative care benefit for Medicare Advantage, Medicare private fee-for-service (PFFS) and Medicaid plan members when it becomes available to the public.
People exposed to a H1NI strain of influenza A while in utero were significantly more likely to have cardiovascular disease later in life, reveals a new study to be published in Journal of Developmental Origins of Health and Disease on Oct. 1.
According to an article in the Wall Street Journal, the H1N1 swine flu could be severe enough to cause major staffing shortages and other workplace disruptions, the supply of vaccines to prevent the disease is taking longer to produce than originally forecast.
A majority (58%) of Americans believe that the H1N1 flu is a serious health hazard, according to a new survey released today by Silverlink Communications, Inc. This represents a marked increase as compared to May 2009, when 47% of Americans held this same perception of H1N1. While most Americans believe H1N1 is a serious health hazard, less than one-third (31%) of Americans plan on getting the H1N1 flu vaccine this year, with safety and efficacy of the vaccine cited as primary barriers for not getting the vaccine. Of particular concern, less than 27% of 18 to 24 year olds, a high risk group, plan on getting the H1N1 vaccine.
The Pennsylvania Department of Health today discussed the state's distribution plans for the new pandemic H1N1 vaccine.
According to a new Consumer Reports poll, 43 percent of American adults say they're on the fence about getting the swine flu vaccine and just 34 percent of those polled plan on getting the swine flu vaccine when it becomes available. Additionally, a mere 35 percent of parents say they'll definitely have their children vaccinated. The Centers for Disease Control and Prevention recommends that all children over the age of 6 months get the vaccine.
The first H1N1 (swine flu) vaccine shots available in the U.S. were shipped ahead of schedule after the pharmaceutical company Sanofi-Aventis finished production nearly two weeks early, the chief executive of the company said Tuesday, the New York Times reports.
BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.
House Speaker Nancy Pelosi, D-Calif., on Tuesday commended Tanazanian President Jakaya Kikwete on the country's utilization of U.S. aid money and vowed her support for the country's future development projects, during a meeting in Washington, D.C., the Zimbabwean reports. "Pelosi hailed President Kikwete and his government for the commitment demonstrated by the campaigns against HIV/AIDS, malaria and TB and implementation of MCC programmes," the newspaper writes (Kulekana, 9/30).
BioCryst Pharmaceuticals, Inc. today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA). BioCryst management intends to provide an update once the RFP process has reached a conclusion.
As millions of Massachusetts children and teenagers returned to school this month, at the start of a serious flu season, the Northeast Homeland Security Regional Advisory Council (NERAC) has an important health message: "It's Up to You to Stop the Flu."
The latest H1N1 genomic data shows a 50% drop in the Replikin CountTM of the virus’s replikins lethality gene since its recorded highs in April 2009. In contrast, the Replikin Count of the virus’s infectivity gene showed a continued elevation.
As the battle against the H1N1 influenza outbreak continues, hospitals are on the front lines, charged with identifying, treating, monitoring, and reporting flu cases—as well as preventing their spread to other patients and hospital personnel. To facilitate this arduous task, a growing number of U.S. hospitals are using a patient safety surveillance system developed by TheraDoc that helps them more effectively coordinate their responses to this serious public health threat.
Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.
ANXeBusiness Corp., a leading provider of networking and security managed services, today issued advice for IT organizations on the importance of disaster plan readiness, proper employee education and preparation for organizations to maintain business continuity during the H1N1 influenza pandemic.
The issuer's China based operating subsidiary Mellow Hope through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd has been granted H1N1 license on September 24, 2009 by SFDA (China Authority) http://eng.sfda.gov.cn/eng. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales.
Earthquakes, fires, floods, pandemics. The public relies on health professionals, emergency responders and trained volunteers to react appropriately to a range of disasters, big or small. But does everyone understand the systems that are in place to respond to these dreaded events?
Weill Cornell Medical College in Qatar hosted a detailed talk about a virus that's causing concern around the world. The recent cause of an interruption in local school openings, H1N1 information was presented in timely fashion by Dr. Abdullatif Al-Khal, head of the communicable disease unit at Hamad Medical Corporation, and Dr. Ravinder Mamtani, Professor of Public Health at WCMC-Q.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.